Autolus Therapeutics plc, the commercial-stage biopharmaceutical company with dual headquarters in London and Gaithersburg, Maryland, announced on September 9, 2026 that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to obecabtagene autoleucel (obe-cel) for systemic lupus erythematosus (SLE) and lupus nephritis (LN).
Chief Development Officer Dr. Matthias Will said: “SLE and LN are serious autoimmune diseases with a critical unmet need for new therapeutic options, particularly for patients with severe refractory disease. We are grateful to have received the RMAT designation for obe-cel based on the Phase 1b data reported from the CARLYSLE trial and believe it provides an important framework to facilitate efficient development within the LUMINA trial.”
A Cell Therapy Already on the Market, Now Chasing a New Disease
Obe-cel is a programmed T cell therapy already sold under the brand name AUCATZYL® for adults with relapsed/refractory B-cell acute lymphoblastic leukemia, giving Autolus a marketed, FDA-approved product before this designation even arrives. RMAT designation, created under the 21st Century Cures Act, is meant to accelerate the development and regulatory review of regenerative medicine therapies, including cell therapies, aimed at serious or life-threatening diseases; the release doesn’t spell out which specific RMAT benefits, such as early FDA interaction or rolling review, Autolus expects to use. This designation was supported by Phase 1b data from the CARLYSLE trial, though the release doesn’t disclose specific patient numbers, response rates, or safety findings from that study.
Where the Program Goes From Here
Will pointed to the RMAT designation as groundwork for what comes next: “We look forward to continuing to work closely with the FDA as we advance obe-cel through clinical development.” That next step is LUMINA, a pivotal Phase 2 trial currently enrolling patients across five countries, with data expected in 2028. A positive outcome there would extend obe-cel’s use well beyond its current approved indication, adding autoimmune disease to a pipeline Autolus is already building out across hematological malignancies and solid tumors.
About Autolus Therapeutics
Autolus Therapeutics plc is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms, and eliminate these cells. Autolus has a marketed therapy, AUCATZYL®, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases.
